Incredibly proud of what Laura Yecies and the team at Osteoboost Health developed to help women improve #BoneHealth and #womenshealth for #postmenopausal women
With six U.S. patents, commercial rollout underway, and validated outcomes from a pivotal 12-month trial, Osteoboost Health is building what the future of bone health should look like. An AgeTech Collaborative™ from AARP startup, Osteoboost offers the first and only FDA-cleared, drug-free prescription treatment for #osteopenia. Their wearable delivers precision vibration therapy to the hips and spine, areas most at risk of fractures. The results? Clinically proven. Led by seasoned healthtech CEO Laura Yecies (Catch, SugarSync) the team has: - FDA Class II medical device clearance - Completed pivotal trial at University of Nebraska Medical Center - New data presented at Endo 2025 showing 82% adherence and high usability - Nationwide U.S. launch as of May 2025 - Six U.S. patents protecting core vibration therapy technology - Backing from the National Institute on Aging (NIA) and lead investors including Esplanade Ventures, Terumo Medical Corporation, Ambit Health Ventures, Portfolia, Astia & Golden Seeds - A strategy focused on provider, patient, and reimbursement alignment What’s next: > Scaling adoption in women’s health and aging care > Expanding digital adherence tools and exercise programs > Building strategic clinical and distribution partnerships In a sector where safety and credibility are everything, Osteoboost is leading and opening up a new category in bone health intervention. Are you an angel investor looking to learn more? Contact: jazan@agetechcapital.com Michael Jaasma Pamela M. Peeke, MD, MPH, FACP, FACSM Priya Patel Amelia Hay Andy Miller Alan MacIntosh Bruce B. Simpson Lyne Landry, ICD.DJeremie Azan Christele Berthelot-Logsdon #AngelInvesting #Longevity #Healthspan #BoneHealth #ATIN #FDAApproved #AgeTech #DigitalHealth #Prevention #VibrationTherapy #WomenInHealthTech #NonPharma #PrecisionMedicine